CDC recommends suspension of the routine use of the third and fourth doses of pneumococcal conjugate vaccine (Prevnar®)

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  Tuesday, March 02, 2004, 16:26 EST (04:26 PM EST)
  
  CDCHAN-00187-2004-03-02-ADV-N
  
  All health-care providers should temporarily suspend routine use of both the third and fourth doses of pneumococcal conjugate vaccine (PCV7), the Centers for Disease Control and Prevention (CDC) recommended today. Children at increased risk of severe disease should continue to receive the full, routine, four-dose series.
  
  CDC took the action in consultation with the American Academy of Family Physicians (AAFP), the American Academy of Pediatrics (AAP), and the Advisory Committee on Immunization Practices (ACIP), to most effectively use the limited, available doses of until the manufacturer can restore full production. Wyeth Vaccines, the sole manufacturer in the United States, markets PCV7 under the trade name Prevnar®.
  
  
• Subjects:
  Child, Preschool Heptavalent Pneumococcal Conjugate Vaccine Immunization Schedule Infant Meningococcal Vaccines Pneumococcal Vaccines
• Source:
  HAN ; 187
• Series:
  Health Alert Network
• Document Type:
  HAN Health Advisory
• Place as Subject:
  United States
• Pages in Document:
  3 unnumbered pages
• Issue:
  187
• Collection(s):
  Health Alert Network (HAN)
• Main Document Checksum:
  urn:sha-512:fdee252e740935f1327b36795f0da9371b244ccfb93df35e56b3d97d645506dcb75693511e3b5c0bed848f2de89f3324d11ba2dc51daeee80043173903d920e3
• Download URL:
  https://stacks.cdc.gov/view/cdc/25098/cdc_25098_DS1.pdf
• File Type:
  [PDF - 750.63 KB ]